Many men, after they have had a radical prostatectomy, find that their testosterone levels are low and are desirous of supplementing their testosterone. (This low level of testosterone is not a result of the surgery). One way of supplementing androgens is by transdermal testosterone-replacement therapy (TRT), but TRT also has the undesirable effect of increasing [...]
Conversations among survivors and evidence in the literature suggests that there is a positive association between serum 25-hydroxyvitamin D [25(OH)D] (vitamin D3) and survival in certain types of cancer, including advanced prostate cancer. Researchers from the Cancer Treatment Centers of America investigated the relationship between survival advantage and vitamin D3 levels in [...]
According to a news from CNN a short time ago the FDA shut down 1,677 online pharmacies. It was reported that 58 people were arrested and that 41 million dollars worth of illegal, counterfeit drugs were seized from 100 different countries. According to The National Association of Boards of Pharmacy there are over 10,000 online [...]
Researchers at Duke University observed a survival benefit for men who had salvage radiation therapy (RT) for prostate-specific antigen (PSA) failure after radical prostatectomy (RP) in the men who experience a rapid rises in PSA doubling time (DT,< 6 months). They then asked whether such a benefit also exits in men with a protracted PSA [...]
The treatment of advanced prostate cancer, and in particular castrate resistant prostate cancer (CRPC), has changed greatly over the last 4 years. Treatment options have expanded and now offer multiple treatment possibilities that did not exist 4 years ago. With the addition of all these new options, so comes the addition of significant economic costs, [...]
The great news for for our brothers in Europe is that Xtandi (Enzalutamide) has been approved for use in the European Union (EU) for the treatment of men with metastatic castration-resistant prostate cancer whose disease has progressed on or after chemotherapy (docetaxel). Following the regulatory review process by the European Medicines Agency (EMA) and a [...]
Infections are among the scariest possibility whenever we go into the hospital, especially for any type of surgery. The good news is that since 2008 the national rates of certain hospital infections have declined significantly. We cancer survivors are more vulnerable to infection since many of our treatments including chemotherapy temporarily suppress our immune systems. [...]
Start A Cure Update -What Went Wrong: Eliminating Mistakes in Diagnosis and Treatment of Prostate Cancer Malecare’s Start A Cure web site has begun to function in earnest. We at Malecare have become concerned about the increasing loss of funding for prostate cancer research, so we have started a “crowd funding” project to let individuals [...]
Why does PSA continue to rise and prostate cancer disease continue to progress (new tumors develop and existing tumors continue to get bigger) when a man has an immune system treatment to go after their prostate cancer? This issue is probably the major marketing hurdle faced by Dendreon’s Provenge and based on the current statistics [...]
Many of us believe that prostate cancer is one specific disease, however this is not true. In fact we now know that there are at least twenty-three different types off prostate cancer. The most common types of prostate cancer, or ninety-five percent of them are referred to as adenocarcinomas. One of the least common types [...]
